TNF and inflammatory bowel disease: Anti-S levels were comparable between all treatments in the non-anti-TNFα group, further supporting our decision to include them in the same group—specifically, treatment with 5ASA (n = 19), vedolizumab (n = 18), no medical treatment (n = 19), and all other IBD medications (steroids (n = 2), immunomodulators (n = 2), ustekinumab (n = 9), and JAK inhibitors (n = 4); see Table 1, Figure S1).